Search

Your search keyword '"HemispheRx BioPharma Inc. -- Product development"' showing total 11 results
Start Over Descriptor "HemispheRx BioPharma Inc. -- Product development" Journal globenewswire
11 results on '"HemispheRx BioPharma Inc. -- Product development"'

1. Hemispherx Announces the First Participant Received Initial Dosing in Breast Cancer Clinical Trial Using Hemispherx' Ampligen and Pembrolizumab

Subjects
Merck & Company Inc. -- Product development, HemispheRx BioPharma Inc. -- Product development, Pharmaceutical industry -- Product development, Breast cancer, Clinical trials, Pembrolizumab, Parks, Cancer metastasis, Banking, finance and accounting industries, Business, Ampligen (Medication)
Abstract

OCALA, Apr 02, 2019 (GLOBE NEWSWIRE via COMTEX) -- (NYSE American: HEB) -- Hemispherx today announced active initiation of a clinical trial sponsored by Roswell Park Comprehensive Cancer Center (Roswell [...]

Published
2019

2. Hemispherx Biopharma Signs Clinical Trial Agreement with Roswell Park Comprehensive Cancer Center to Study Ampligen in Combination with Checkpoint Inhibitors in a Phase IIa Study in Urothelial Carcinoma, Renal Cell Carcinoma and Melanoma

Subjects
HemispheRx BioPharma Inc. -- Product development, Clinical trials, Cancer research, Parks -- United States, Melanoma, Renal cell carcinoma, Biological products industry -- Product development, Banking, finance and accounting industries, Business, Ampligen (Medication)
Abstract

OCALA, Fla., Oct 10, 2018 (GLOBE NEWSWIRE via COMTEX) -- Hemispherx Biopharma, Inc. (NYSE American: HEB) announces the signing of a clinical trial agreement with Roswell Park Comprehensive Cancer Center [...]

Published
2018

3. Hemispherx Biopharma Announces Identification of High Responder Patient Subgroup from Ampligen(R) Phase III Trial in Patients with CFS/ME

Subjects
HemispheRx BioPharma Inc. -- Product development, Clinical trials, Chronic fatigue syndrome -- Care and treatment, Biological products industry -- Product development, Banking, finance and accounting industries, Business, Alferon N (Medication), Ampligen (Medication)
Abstract

PHILADELPHIA, Oct 31, 2016 (GLOBE NEWSWIRE via COMTEX) -- 51% of patients in the high responder subset receiving Ampligen vs. 18% of placebo patients demonstrated improvement of at least 25% [...]

Published
2016

4. Hemispherx Biopharma Conducts an Interview with The Wall Street Transcript

Subjects
HemispheRx BioPharma Inc. -- Product development, Interferon -- Product development, Biological products industry -- Product development, Banking, finance and accounting industries, Business, Alferon N (Medication), Ampligen (Medication)
Abstract

PHILADELPHIA, Aug 15, 2016 (GLOBE NEWSWIRE via COMTEX) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the 'Company' or 'Hemispherx') has posted the transcript of The Wall Street Transcript interview with Thomas [...]

Published
2016

5. Hemispherx Biopharma Reports Article by Senior Authors From Italian Ministry of Health and Related Agencies Suggesting Broad Applicability of Ampligen(R) to Multiple Sclerosis

Subjects
HemispheRx BioPharma Inc. -- Product development, Multiple sclerosis, Biological products industry -- Product development, Banking, finance and accounting industries, Business, Ampligen (Medication)
Abstract

PHILADELPHIA, Sep 23, 2015 (GLOBE NEWSWIRE via COMTEX) -- Hemispherx Biopharma (NYSE MKT:HEB) announced today a new peer reviewed article, with senior authors from the Italian Ministry of Health and [...]

Published
2015

6. Hemispherx Biopharma Research Team Identifies Characteristics of Chronic Fatigue Syndrome (CFS) Patients Potentially Predictive of Improved Response to Ampligen

Subjects
HemispheRx BioPharma Inc. -- Product development, Chronic fatigue syndrome, Medical research, Biological products industry -- Product development, Banking, finance and accounting industries, Business, Alferon N (Medication), Ampligen (Medication)
Abstract

PHILADELPHIA, Sep 21, 2015 (GLOBE NEWSWIRE via COMTEX) -- Hemispherx Biopharma (NYSE MKT:HEB) announces the publication of an online peer reviewed research article of an analysis of clinical data on [...]

Published
2015

7. FDA Authorizes Expansion of Ampligen/FluMist Intranasal Clinical Trial Designed to Elicit Potential Protection Against Many Pre-Pandemic Influenza Viruses

Subjects
United States. Food and Drug Administration, HemispheRx BioPharma Inc. -- Product development, Biological products industry -- Product development, Influenza viruses, Influenza, Clinical trials, Vaccines -- Product development, Banking, finance and accounting industries, Business, Alferon N (Medication), Ampligen (Medication)
Abstract

PHILADELPHIA, Dec 09, 2013 (GLOBE NEWSWIRE via COMTEX) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the 'Company' or 'Hemispherx') today announced that its Phase 1/2 clinical trial at the University of [...]

Published
2013

8. Hemispherx Biopharma and the FDA Reach Agreement on Filing Requirements for the Company's Complete Response in Support of Ampligen(R) New Drug Application for Chronic Fatigue Syndrome Treatment

Subjects
United States. Food and Drug Administration, HemispheRx BioPharma Inc. -- Product development, Biological products industry -- Product development, Chronic diseases, Chronic fatigue syndrome, Banking, finance and accounting industries, Business, Ampligen (Medication)
Abstract

Byline: Staff PHILADELPHIA, Jul 11, 2012 (GlobeNewswire via COMTEX) -- Hemispherx Biopharma, Inc. (NYSE:HEB) (the 'Company' or 'Hemispherx') recently met with representatives of the U.S. Food and Drug Administration (the [...]

Published
2012

9. FDA Authorizes New Hemispherx Biopharma Clinical Trial of Intranasal Ampligen(R) With Seasonal Influenza Vaccine

Subjects
HemispheRx BioPharma Inc. -- Product development, Biological products industry -- Product development, Influenza vaccines -- Product development, Influenza -- Drug therapy, Clinical trials, Banking, finance and accounting industries, Business, Ampligen (Medication)
Abstract

Byline: Staff PHILADELPHIA, Jul 20, 2011 (GlobeNewswire via COMTEX) -- Hemispherx Biopharma, Inc. (NYSE Amex:HEB) (the 'Company' or 'Hemispherx') today announced it has received U.S. Food Drug Administration (FDA) authorization [...]

Published
2011

10. Hemispherx Biopharma Prepares Application to Initiate Phase II Clinical Trials in China With Ampligen(R)

Subjects
HemispheRx BioPharma Inc. -- Product development, Biological products industry -- Product development, Medical research, Medicine, Experimental, Clinical trials, Banking, finance and accounting industries, Business, Ampligen (Medication)
Abstract

Byline: Staff PHILADELPHIA, May 17, 2010 (GlobeNewswire via COMTEX) -- As part of its expanding international program Hemispherx Biopharma, Inc. (NYSE Amex:HEB), (the 'Company'), announced an agreement with Fountain Medical [...]

Published
2010

11. New Independent Data Monitoring Committee Established by Hemispherx to Accelerate Global Drug Development

Subjects
HemispheRx BioPharma Inc. -- Product development, Medical research, Medicine, Experimental, Pharmaceutical industry -- Product development, Banking, finance and accounting industries, Business, Alferon N (Medication)
Abstract

Byline: Staff PHILADELPHIA, May 3, 2010 (GlobeNewswire via COMTEX) -- Hemispherx Biopharma, Inc. (NYSE AMEX:HEB) (the 'Company') announced today the formation of an Independent Data Monitoring Committee (DMC) which will [...]

Published
2010

Catalog

Books, media, physical & digital resources
See catalog results